Inhibrx Stock Valuation

INBX -  USA Stock  

USD 25.87  2.19  7.80%

Do you wonder what the value of Inhibrx is? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Inhibrx, is its stock price multiplied by the total number of shares outstanding, calculating Inhibrx's enterprise value requires a different approach. It uses Inhibrx's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Tangible Asset Value is likely to rise to about 178.4 M in 2022, whereas Free Cash Flow is likely to drop (47.9 M) in 2022.
Inhibrx retains a regular Real Value of $32.43 per share. The prevalent price of the firm is $25.87. At this time, the firm appears to be undervalued. Our model calculates the value of Inhibrx from evaluating the firm fundamentals such as Shares Owned by Insiders of 39.91 %, return on asset of (34.04) %, and Return On Equity of (130.46) % as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage acquiring undervalued assets and dropping overvalued assets since, at some point, asset prices and their ongoing real values will come together.

Inhibrx Valuation 

Inhibrx Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Inhibrx's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
24th of January 2022
Please note that Inhibrx's price fluctuation is not too volatile at this time. Calculation of the real value of Inhibrx is based on 24 months time horizon. Increasing Inhibrx's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Inhibrx is useful when determining the fair value of the Inhibrx stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Inhibrx. Since Inhibrx is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Inhibrx Stock. However, Inhibrx's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Real Value
Estimating the potential upside or downside of Inhibrx helps investors to forecast how Inhibrx stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Inhibrx more accurately as focusing exclusively on Inhibrx's fundamentals will not take into account other important factors:
Estimates (2)
LowProjected EPSHigh
LowEstimated ValueHigh
LowNext ValueHigh
3 Analysts
LowTarget PriceHigh
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Inhibrx's intrinsic value based on its ongoing forecasts of Inhibrx's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Inhibrx's closest peers. When choosing an evaluation method for Inhibrx, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Inhibrx Valuation Drivers Correlation

Many accounts on the financial statements of Inhibrx are highly interrelated and sometimes correlated. Consequently, when conducting Inhibrx's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Inhibrx
Click cells to compare fundamentals

Inhibrx Valuation Trend

Knowing Inhibrx's actual value is paramount for traders to make sound investment determinations. Inhibrx's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Inhibrx's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Inhibrx's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Inhibrx Market Cap

Inhibrx is rated second overall in market capitalization category among related companies. Market capitalization of Biotechnology industry is currently estimated at about 3.72 Billion. Inhibrx totals roughly 1.06 Billion in market capitalization claiming about 29% of stocks in Biotechnology industry.
Capitalization  Total debt  Valuation  Revenue  Workforce

Inhibrx Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Inhibrx's current stock value. Our valuation model uses many indicators to compare Inhibrx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inhibrx competition to find correlations between indicators driving Inhibrx's intrinsic value. More Info.
Inhibrx is currently regarded as number one stock in price to book category among related companies. It is currently regarded as number one stock in price to sales category among related companies fabricating about  3.94  of Price to Sales per Price to Book. Price to Sales Ratio is likely to drop to 57.82 in 2022. Comparative valuation analysis is a catch-all model that can be used if you cannot value Inhibrx by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Inhibrx's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inhibrx's earnings, one of the primary drivers of an investment's value.

About Inhibrx Valuation

The equity valuation mechanism determines the current worth of Inhibrx on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Inhibrx. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Inhibrx based exclusively on its fundamental and basic technical indicators. By analyzing Inhibrx's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Inhibrx's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Inhibrx. We calculate exposure to Inhibrx's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Inhibrx's related companies.
Last ReportedProjected for 2022
Gross Profit14.8 M14.5 M
Profit Margin(5.32) (5.74) 
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.

Inhibrx Quarterly Enterprise Value

1.21 BillionShare

Inhibrx Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Inhibrx does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio4.50
Revenue Growth-57.10%
Enterprise Value To Ebitda-20.00
Enterprise Value To Revenue204.47

Inhibrx Current Valuation Indicators

Valuation refers to the process of determining the present value of Inhibrx and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Inhibrx we look at many different elements of the entity such as Inhibrx's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Inhibrx, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Inhibrx's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Inhibrx's worth.
Please see Risk vs Return Analysis. Note that the Inhibrx information on this page should be used as a complementary analysis to other Inhibrx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Inhibrx Stock analysis

When running Inhibrx price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Is Inhibrx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibrx. If investors know Inhibrx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibrx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Inhibrx is measured differently than its book value, which is the value of Inhibrx that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibrx's value that differs from its market value or its book value, called intrinsic value, which is Inhibrx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibrx's market value can be influenced by many factors that don't directly affect Inhibrx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibrx's value and its price as these two are different measures arrived at by different means. Investors typically determine Inhibrx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibrx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.